SK pharmteco Partners with OTXL to Advance Rare Disease Therapies
Friday, June 19, 2026
SK pharmteco has entered into a strategic collaboration with the Orphan Therapeutics Accelerator (OTXL) to support the development and manufacturing of treatments for rare diseases.
The partnership is part of SK pharmteco’s Rare Disease Advancement Initiative, which aims to speed up the development of therapies for conditions with significant unmet medical needs. Under the agreement, SK pharmteco will act as OTXL’s preferred technical partner, providing manufacturing and development expertise to help advance therapeutic programmes towards clinical and commercial milestones.
Through the collaboration, SK pharmteco will offer OTXL priority access and preferential pricing for up to two therapeutic programmes each year. The company will support these programmes with a range of services, including process development, analytical development, and GMP manufacturing with quality control release.
Process development activities will focus on optimising and scaling manufacturing processes for complex therapies. Analytical development will involve creating testing methods to support product safety and molecular characterisation. GMP manufacturing and quality control services will help ensure regulatory compliance and product quality for clinical use.
The partnership is designed to reduce manufacturing challenges that can slow the progress of rare disease treatments and to support the transition of promising therapies from development to commercialisation. By combining SK pharmteco’s manufacturing capabilities with OTXL’s rare disease programmes, the organis
Source: skpharmteco.com
